Top

Published in:

01-06-2005 | Poster Presentation

6-(1-oxobutyl)-5,8-dimethoxy-1,4-naphthoquinone exerts anti-angiogenic activity via inhibition of vascular endothelial cell growth factor and hypoxia-inducible factor 1 alpha in hypoxia-exposed MCF breast cancer cells

Authors: HJ Lee, SH Kim

Published in: Breast Cancer Research | Special Issue 2/2005

Excerpt

Hypoxia induces the transcription of various genes involved in angiogenesis and anaerobic metabolism necessary for the growth of tumor cells. Hypoxia-inducible factor 1 alpha (HIF-1α) regulates genes involved in the response to hypoxia and promotes neo-angiogenesis in cancer. Thus, to develop an anticancer agent with anti-angiogenic activity in hypoxic cancer cells, 6-(1-oxobutyl)-5,8-dimetoxy-1,4-naphthoquinone (OXO) was synthesized. …

Song G-Y, Kim Y, You YJ, Cho H, Kim SH, Sok DE, Ahn BZ: Naphtazarin derivatives (VI): synthesis, inhibitory effect on DNA topoisomerase-I and antiproliferative activity of 2- or 6-(1-oxyiminoalkyl)-5,8-dimethoxy-1,4-napthoquinones. Arch Pharm Pharm Med Chem. 2000, 333: 87-92. 10.1002/(SICI)1521-4184(20004)333:4<87::AID-ARDP87>3.0.CO;2-1.CrossRef

Forsythe JA, Jiang BH, Lyer NV, Agani F, Leung SW, Koos RD, et al: Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol. 1996, 16: 4604-4613.CrossRefPubMedPubMedCentral

Richard DE, Berra E, Pouyssegur J: Angiogenesis: how a tumor adapts to hypoxia. Biochem Biophys Res Commun. 1999, 266: 718-722. 10.1006/bbrc.1999.1889.CrossRefPubMed

Ferrara H, Gerber H-P, Lecouter J: The biology of VEGF and its receptors. Nat Med. 2003, 9: 669-676. 10.1038/nm0603-669.CrossRefPubMed

Title: 6-(1-oxobutyl)-5,8-dimethoxy-1,4-naphthoquinone exerts anti-angiogenic activity via inhibition of vascular endothelial cell growth factor and hypoxia-inducible factor 1 alpha in hypoxia-exposed MCF breast cancer cells
Authors: HJ Lee
SH Kim
Publication date: 01-06-2005
Publisher: BioMed Central
Published in: Breast Cancer Research / Issue Special Issue 2/2005
Electronic ISSN: 1465-542X
DOI: https://doi.org/10.1186/bcr1131

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Special Issue 2/2005

ERβ in normal and malignant breast

Ex vivo isolation of adult stem cells from normal and tumour mouse mammary parenchyma

BRCA1 directly modulates gene expression required for estrogen biosynthesis: a possible mechanism of tissue-specific tumor suppression

Development of a rapid screening approach for candidate gene sets in cancer

Breast tumors induce the recruitment of AC133+KDR+ endothelial precursor cells mobilized by plasma vascular endothelial growth factor

Mapping the location of recurring amplicons in array-CGH data

Keynote webinar | Spotlight on antibody–drug conjugates in cancer